

Bakers Union and FELRA Health and Welfare Fund

Quarterly Review
January – September 2023

December 6, 2023



Today's Topics

1. Key Discussion Topics
2. Performance Summary
3. Trend
4. Top Disease States
5. Rebates
6. Outcomes
 - Clinical Outcomes
 - Vigilant Outcomes
 - VCS Outcomes
7. Drug Pipeline

Your OptumRx Team

Paul Marcus

VP, Client Management
Labor & Trust

Holly Agoney

Strategic Account Executive
Labor & Trust

Caroline Atwood

Director, Client
Management
Labor & Trust

Autumn Leblanc

Pharmacy Account
Manager
Labor & Trust

Fabian Gonzales

Pharmacy Service
Specialist
Labor & Trust

Current Plan Design

☐ Deductible, Ben Max, MOOP, Copays

Plan 1 (group BFWRX):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$2,850 Individual / \$5,700 Family

Plan 2 (group BFWRX2) & Plan 3 (group BFWRX3):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$1,850 Individual / \$3,700 Family

Co-pays			
Plan 1 (group BFWRX) & Plan 2 (group BFWRX2):			
	Retail		Mail
*Generic:	\$10	*Generic:	\$20
*Brand:	\$15	*Brand:	\$30
*NP Brand:	\$30	*NP Brand:	\$60
*Specialty:	Run trial claim for co-pay		*Specialty: N/A

Plan 3 (group BFWRX3):		
Retail / Mail		
*Generic:	5%	(\$5 min.)
*Brand:	15%	(\$15 min.)
*NP Brand:	25%	(\$25 min.)
*Specialty:	Run trial claim for co-pay	

☐ Effective 7/1/19

- ☐ Diabetes Program
- ☐ Comprehensive Ums
- ☐ Vigilant Program
- ☐ RxOTC Program

☐ Effective 8/1/2020

- ☐ Orphan Drug Program

☐ Effective 3/1/2021

- ☐ Opioid Mgmt – tighter refill window & UMs

☐ Effective 7/1/2021

- ☐ Premium Formulary
- ☐ Mandatory Mail (MSS)

☐ Effective 1/1/2022

- ☐ Split-fill/Smart-fill

☐ Effective 3/1/2022

- ☐ CCAA/VCS

☐ Effective 5/15/23

- ☐ Price Edge

Key Discussion Topics

- ❑ Per Member Per Month (PMPM) trend = 44.2% Specialty trend = 218.5%
- ❑ Specialty represents 1.2% of claims

- ❑ Top 5 disease states accounted for 75% of total plan paid
 - ❑ Top traditional disease state: Diabetes
 - ❑ Top specialty disease state: Inflammatory Conditions

- ❑ Rebates – January – Sept 2023
 - ❑ Estimated - \$151,200

- ❑ Clinical Outcomes savings
 - ❑ **UM (PA, ST, QL)** – Oct 2022 – Sept 2023
 - ❑ Savings = \$182,100
 - ❑ **Vigilant** – Oct 2022 – Sept 2023
 - ❑ Savings = \$12,595
 - ❑ **VCS** – Jan - Sept 2023
 - ❑ Savings = \$8,664


Key Statistics

Key Statistics – Performance Summary

Plan paid PMPM: \$171.29

[View plan performance](#)

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -44.
- Number of utilizers has decreased by -49.

Total Rx's

CURRENT

5,188

PREVIOUS

5,888

PERCENT CHANGE

-11.9%

Total plan paid

CURRENT

\$892,430

PREVIOUS

\$666,236

PERCENT CHANGE

34.0%

Utilizers

CURRENT

388

PREVIOUS

437

PERCENT CHANGE

-11.2%

Key Statistics

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 44.2%, compared to the benchmark trend of 13.0%
- Member Paid Share changed by -26.0% period over period, compared to the benchmark of -9.0%


Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Average age	44.0	43.0	2.5%	37.2	0.2%	36.8	0.2%
Plan paid PMPM	\$171.29	\$118.78	44.2%	\$127.24	13.0%	\$131.92	15.5%
Plan paid per Rx	\$172.02	\$113.15	52.0%	\$182.87	12.6%	\$168.64	16.3%
Rxs PMPM	0.996	1.050	-5.1%	0.696	0.4%	0.782	-0.7%
Average days supply	30.9	29.6	4.6%	42.0	0.7%	40.4	2.7%
Days supply PMPM	30.8	31.0	-0.8%	29.2	1.1%	31.6	2.0%
Member paid share	6.8%	9.2%	-26.0%	8.2%	-9.0%	11.7%	-7.5%
Member paid per Rx	\$12.53	\$11.42	9.7%	\$16.40	1.5%	\$22.37	6.4%
Generic dispensing rate	84.3%	82.7%	2.0%	87.7%	1.7%	86.9%	1.6%
GDR-without Vaccines	86.1%	86.2%	-0.1%	88.5%	-0.2%	88.0%	-0.2%
Home delivery rate	6.3%	4.8%	31.3%	8.6%	-2.8%	5.1%	2.9%
Retail 90 rate	1.8%	1.4%	25.5%	20.5%	1.0%	20.9%	4.9%
Percent of specialty plan paid	43.3%	19.6%	120.8%	47.1%	-0.3%	51.3%	-0.5%

Specialty Key Statistics

Plan Paid PMPM: \$74.23

[View plan performance](#)

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -44.
- Number of utilizers has increased by 4.

Total Rxs

CURRENT

63

PREVIOUS

55

PERCENT CHANGE

14.5%

Total plan paid

CURRENT

\$386,743

PREVIOUS

\$130,735

PERCENT CHANGE

195.8%

Utilizers

CURRENT

10

PREVIOUS

6

PERCENT CHANGE

66.7%

Specialty Key Statistics

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 218.5%, compared to the benchmark trend of 12.7%
- Member Paid Share changed by -47.1% period over period, compared to the benchmark of -19.1%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Plan Paid PMPM	\$74.23	\$23.31	218.5%	\$59.98	12.7%	\$67.68	14.9%
Plan paid per Rx	\$6,138.77	\$2,377.00	158.3%	\$6,464.86	5.0%	\$6,266.07	7.0%
Rxs PMPM	0.012	0.010	23.3%	0.009	7.4%	0.011	7.4%
Average days supply	39.9	29.0	37.6%	33.3	1.2%	32.3	1.1%
Days supply PMPM	0.5	0.3	69.7%	0.3	8.7%	0.3	8.6%
Member paid share	2.3%	4.4%	-47.1%	4.4%	-19.1%	6.0%	-16.7%
Member paid per Rx	\$147.29	\$110.20	33.7%	\$297.72	-16.0%	\$401.84	-12.1%
Generic dispensing rate	14.3%	49.1%	-70.9%	21.7%	1.6%	21.7%	-2.6%
Home delivery rate	1.6%	1.8%	-12.7%	5.3%	5.3%	3.7%	6.5%
Retail 90 rate	17.5%	0.0%	0.0%	6.8%	4.4%	5.7%	4.3%


Trend Summary

Trend Summary

Trend

Plan paid PMPM has increased 44.2% over the previous period driven primarily by cost in traditional and drug mix for specialty.

Specialty represents 1.2% of claims.



+31.2% over benchmark



-11.6% under benchmark




+205.8% over benchmark

Traditional vs. Specialty Trend Components

Traditional trend: 1.7%

Benchmark comparison: LABOR AND TRUST


- Traditional trend contributed 3.0% to the overall trend (44.2%)
- Traditional accounts for 56.7% of overall total plan paid and was down from 80.4% in the prior period



Specialty trend: 218.5%

Benchmark comparison: LABOR AND TRUST

- Specialty trend contributed 97.0% to the overall trend (44.2%)
- Specialty accounts for 43.3% of overall total plan paid and was up from 19.6% in the prior period



Top Disease States & Top 20 Drugs

Top Disease States

Top 5 disease states account for 75% of total Plan Paid

- Inflammatory Conditions accounts for 30.0% of total plan paid, with trend driven by Utilization. DUPIXENT was the top drug
- Diabetes accounts for 25.8% of total plan paid, with trend driven by Drug Mix. JARDIANCE was the top drug

Sort by: Plan Paid

Inflammatory Conditions ▲

PMPM
\$51.43

Trend
133.4%

Top driver:
Utilization

Diabetes ▲

PMPM
\$44.28

Trend
39.7%

Top driver:
Drug Mix

Oncology ▲

PMPM
\$17.88

Trend
5,521.8%

Top driver:
Drug Mix

Cardiovascular ▲

PMPM
\$8.61

Trend
7.6%

Top driver:
Utilization

Asthma / COPD ▼

PMPM
\$6.67

Trend
-50.2%

Top driver:
Utilization

All other ▼

PMPM
\$42.42

Trend
-2.2%

Top 20 Drugs by Plan Cost

All meds are Brands except indicated with a "G" for generic

Specialty

Rank														Trend components		
Cu ↕	Pv ↕	Bench ↕	Drug name ↕	Therapy class ↕	Utilizr ↕	Rxs ↕	Avg days supply ↕	Total plan paid ↕	Plan paid per Rx ↕	Curr plan paid PMPM ↕	Prev plan paid PMPM ↕	Bench plan paid PMPM ↕	% Trend ↕	Top driver ↕	% Top driver ↕	
1	1	6	DUPIXENT	Chronic Inflammatory Disease	4	31	27.5	\$106,016	\$3,419.86	\$20.35	\$11.35	\$3.11	79.2%	Utilzn	72.8%	
2	-	7	SKYRIZI PEN	Chronic Inflammatory Disease	1	4	43.0	\$81,374	\$20,343.62	\$15.62	\$0.00	\$2.73	- -	-	-	
3	2	1	HUMIRA PEN	Chronic Inflammatory Disease	1	9	28.0	\$64,162	\$7,129.14	\$12.32	\$9.98	\$8.73	23.4%	Cost	9.6%	
4	-	87	KISQALI	Oncology	1	4	28.0	\$80,778	\$15,194.42	\$11.67	\$0.00	\$0.26	- -	-	-	
5	-	31	BRANCE	Oncology	1	2	28.0	\$31,090	\$15,545.22	\$5.97	\$0.00	\$0.74	- -	-	-	
6	8	4	JARDIANCE	★ SGLT-2 Inhibitors & Combos	7	44	36.8	\$29,522	\$670.95	\$5.67	\$3.11	\$3.60	82.1%	Utilzn	71.0%	
7	21	2	OZEMPIC	★ GLP-1 Receptor Agonists	5	16	53.2	\$25,371	\$1,585.71	\$4.87	\$1.29	\$5.73	277.9%	Utilzn	264.0%	
8	7	5	TRULICITY	★ GLP-1 Receptor Agonists	5	29	28.3	\$25,229	\$869.95	\$4.84	\$3.33	\$3.32	45.6%	Utilzn	37.1%	
9	-	508	TRIPTODUR	LHRH/GNRH Agonist/Antagonists	1	1	168.0	\$19,771	\$19,770.81	\$3.79	\$0.00	\$0.03	- -	-	-	
10	6	58	VICTOZA	★ GLP-1 Receptor Agonists	2	12	42.5	\$17,876	\$1,489.68	\$3.43	\$3.60	\$0.39	-4.6%	Utilzn	-8.5%	
11	64	9	MOUNJARO	★ GLP-1 Receptor Agonists	4	18	28.4	\$17,184	\$954.65	\$3.30	\$0.33	\$2.46	887.8%	Utilzn	884.3%	
12	4	10	BIKTARVY	HIV-Multiclass Combo	1	4	30.0	\$13,077	\$3,269.17	\$2.51	\$4.11	\$2.11	-38.9%	Utilzn	-38.5%	
13	29	13	FARXIGA	★ SGLT-2 Inhibitors & Combos	5	24	30.0	\$12,988	\$541.16	\$2.49	\$0.93	\$1.72	167.4%	Utilzn	158.4%	
14	12	26	ENTRESTO	Angiotensin II Receptor & Nephylisin Inhibitor (ARNI)	2	12	50.0	\$12,417	\$1,034.78	\$2.38	\$1.88	\$0.91	26.5%	Utilzn	19.6%	
15	11	44	JANUMET	★ DPP-4 Inhibitors & Combos	3	19	36.3	\$11,864	\$624.42	\$2.28	\$2.42	\$0.48	-6.0%	Utilzn	-11.6%	
16	16	16	JANUVIA	★ DPP-4 Inhibitors & Combos	3	22	30.0	\$11,092	\$504.20	\$2.13	\$1.59	\$1.48	33.5%	Utilzn	31.6%	
17	38	18	OTEZLA	Chronic Inflammatory Disease	1	2	30.0	\$9,465	\$4,732.70	\$1.82	\$0.70	\$1.25	158.6%	Cost	158.6%	
18	31	24	HUMALOG KWIKPEN	★ Insulin	6	21	26.5	\$9,444	\$449.72	\$1.81	\$0.85	\$0.95	114.4%	Utilzn	113.4%	
19	13	19	LANTUS SOLOSTAR	Insulin ★	10	26	36.1	\$8,998	\$346.07	\$1.73	\$1.78	\$1.23	-3.1%	Cost	-19.8%	
20	3	280	STRIBILD	HIV-Multiclass Combo	1	2	30.0	\$8,621	\$4,310.33	\$1.65	\$5.24	\$0.06	-68.4%	Utilzn	-73.1%	
Total					41	302	34.2	\$576,339	\$1,908.41	\$110.62	\$52.50	\$41.29	110.7%		55.1%	
Plan Total					388	5,188	30.9	\$892,430	\$172.02	\$171.29	\$118.78	\$127.24	44.2%		38.0%	

Rebates


Rebate Performance Summary

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Sep 2023

Benchmark: LABOR AND TRUST

Current rebate value: \$29.02 PMPM



Rebate impact on Plan Paid PMPM

Managing drug spend to a lowest net cost PMPM is achieved through adoption of high performing formulary strategies and driving to lowest net cost products when clinically appropriate. Bakers Union and FELRA Health and Welfare Fund's members adherence to the formulary has earned an offset on PMPM costs, yielding a net plan paid PMPM of \$142.27, versus plan paid PMPM of \$171.29.

Net financial PMPM performance

	Drug cost	Member Paid	Plan Paid	Rebates	Net plan paid
Traditional	\$107.73	\$10.69	\$97.06	\$19.78	\$77.29
Specialty	\$76.01	\$1.78	\$74.23	\$9.24	\$64.99
Total	\$183.75	\$12.47	\$171.29	\$29.02	\$142.27

Total estimated rebate yield for reporting period: **\$151.2K**

Rebate Performance by Disease State

Disease	Drug cost PMPM	Member paid PMPM	Plan paid PMPM	Rebates PMPM	Net plan paid PMPM	Rebate offset
Diabetes	\$46.68	\$2.40	\$44.28	\$11.23	\$33.05	25.4%
Inflammatory Conditions	\$53.17	\$1.73	\$51.43	\$8.04	\$43.39	15.6%
Asthma / COPD	\$7.05	\$0.38	\$6.67	\$2.39	\$4.28	35.8%
Cardiovascular	\$10.64	\$2.03	\$8.61	\$1.50	\$7.11	17.4%
Oncology	\$17.93	\$0.04	\$17.88	\$1.03	\$16.86	5.7%
Diabetic Supplies	\$2.78	\$0.17	\$2.61	\$0.95	\$1.66	36.3%
Blood Clot Prevention/Stroke Prevention	\$3.11	\$0.15	\$2.96	\$0.88	\$2.08	29.8%
Gastrointestinal, Misc	\$1.18	\$0.07	\$1.11	\$0.35	\$0.76	31.4%
HIV	\$5.23	\$0.39	\$4.83	\$0.32	\$4.51	6.7%
Ophthalmic Agents	\$1.25	\$0.13	\$1.12	\$0.29	\$0.83	26.2%
Overactive Bladder / Incontinence	\$1.09	\$0.06	\$1.04	\$0.29	\$0.75	28.0%
Male And Female Hormone Replacement	\$0.96	\$0.08	\$0.88	\$0.29	\$0.59	32.7%
Weight Loss	\$1.51	\$0.02	\$1.49	\$0.25	\$1.24	16.5%
Glaucoma	\$1.31	\$0.10	\$1.21	\$0.22	\$0.99	18.5%
Contraception	\$1.40	\$0.04	\$1.36	\$0.22	\$1.14	16.5%
Endocrine And Metabolic	\$3.99	\$0.01	\$3.98	\$0.17	\$3.80	4.4%
Kidney Disease	\$0.98	\$0.03	\$0.95	\$0.16	\$0.79	16.7%
Migraine/Pain Relief	\$0.95	\$0.14	\$0.81	\$0.10	\$0.72	11.8%
Cholesterol Lowering Agents	\$3.87	\$1.14	\$2.72	\$0.08	\$2.65	2.8%
Antibiotics	\$1.59	\$0.28	\$1.31	\$0.06	\$1.25	4.8%
Anti-Inflammatory (Steroids)	\$0.10	\$0.07	\$0.04	\$0.03	\$0.00	90.3%
ADHD & Narcolepsy	\$0.04	\$0.00	\$0.04	\$0.03	\$0.01	84.6%
Severe Allergic Reaction	\$0.19	\$0.01	\$0.18	\$0.03	\$0.15	18.0%
Depression	\$2.07	\$0.57	\$1.51	\$0.03	\$1.47	2.2%
Antipsychotics	\$0.51	\$0.04	\$0.47	\$0.03	\$0.44	6.5%
Misc Skin Condition	\$1.62	\$0.19	\$1.43	\$0.03	\$1.40	2.1%


Clinical Outcomes

UM Outcomes

Utilization management savings: \$25.92 PMPM

Your program savings: **\$182.1K**

Ensuring patients meet appropriate clinical criteria when initiating medication therapy not only helps to ensure that the patient is being treated safely according to guidelines, but also drives significant savings for both Bakers Union and FELRA Health and Welfare Fund and for members. Bakers Union and FELRA Health and Welfare Fund has realized over \$182.1K in savings. Based on a study by OptumRx, leveraging UM strategies that drive members to appropriate and often lower cost medications for treatment can save a member up to \$620 annually in out of pocket copayments.



Prior authorization

PMPM SAVINGS

\$9.38

NUMBER OF MEMBERS IMPACTED

40

NUMBER OF INTERVENTIONS

50

Quantity limits

PMPM SAVINGS

\$12.08

NUMBER OF MEMBERS IMPACTED

10

NUMBER OF INTERVENTIONS

10

Step therapy

PMPM SAVINGS

\$4.46

NUMBER OF MEMBERS IMPACTED

77

NUMBER OF INTERVENTIONS

90

QL savings is based only on Maximum Daily Dose edits.

Vigilant Outcomes

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Oct 2022 - Sep 2023

Total program savings: \$1.79 PMPM

Vigilant Drug Outcomes – Cost Avoidance

By leveraging the Vigilant Drug Program, Bakers Union and FELRA Health and Welfare Fund has:

- Avoided \$12.6K in pharmacy spend
- Switched 7 claims to lower cost alternatives
- 6 claims were abandoned



TOTAL PLAN PAID SAVINGS

\$12,595

TOTAL PROGRAM SAVINGS

1.0%

TOTAL MEMBERS IMPACTED

14

Savings by Vigilant Drug List

Sort by: Members impacted Plan paid PMPM savings

Vigilant drug list	PMPM savings	Members impacted	Interventions
High Cost Generics	\$1.50	10	10
Clinical Duplicates	\$0.21	3	3
High Cost Brands with Generics	\$0.07	1	1

VCS (variable copay solutions) Outcomes

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Sep 2023

Total program savings: \$1.66 PMPM

Variable copay program savings outcomes

With the OptumRx Variable Copay program, Bakers Union and FELRA Health and Welfare Fund has realized:

- \$8,664 in Plan Paid savings
- \$1,083.00 average Plan Paid per impacted prescription
- 3 total impacted utilizers

PLAN PAID SAVINGS

\$8,664

PLAN PAID SAVINGS PER IMPACTED RX

\$1,083.00


Top 5 drugs based on: Plan paid savings

DUPIXENT
IMPACTED RXS
8
IMPACTED UTILIZERS
3
PLAN PAID SAVINGS
\$8,664

Drug Pipeline

Selected generic launches in 2023 and 2024

****Fund has Utilization in Drugs in Red****




2022 US Sales

Blockbuster drug
(>\$1B in annual U.S. sales)

[†] Generic has 180-days of exclusivity
HIV = Human Immunodeficiency Virus

Major biosimilars through 2025



* May impact medical benefit due to route of administration Source: 1. 2022 U.S. Sales: IPD Analytics

Appendix


Trend Components



Total trend: 44.2%

Benchmark comparison: LABOR AND TRUST

- Bakers Union and FELRA Health and Welfare Fund's overall trend of 44.2% was 31.2% higher than benchmark
- Specialty spend influenced the trend contributing 97.0% (50.9% higher than benchmark)
- Traditional trend contributed 3.0% (50.9% lower than benchmark)



Top 20 traditional

All meds are Brands

Rank														Trend components		
Cu ↕	Pv ↕	Bench ↕	Drug name ↕		Therapy class ↕	Utilizr ↕	Rxs ↕	Avg days supply ↕	Total plan paid ↕	Plan paid per Rx ↕	Curr plan paid PMPM ↕	Prev paid PMPM ↕	Bench plan paid PMPM ↕	% Trend ↕	Top driver ↕	% Top driver ↕
1	6	2	JARDIANCE	★	SGLT-2 Inhibitors & Combos	7	44	36.8	\$29,522	\$670.95	\$5.67	\$3.11	\$3.60	82.1%	Utilzn	71.0%
2	19	1	OZEMPIC	★	GLP-1 Receptor Agonists	5	16	53.2	\$25,371	\$1,585.71	\$4.87	\$1.29	\$5.73	277.9%	Utilzn	264.0%
3	5	3	TRULICITY	★	GLP-1 Receptor Agonists	5	29	28.3	\$25,229	\$869.95	\$4.84	\$3.33	\$3.32	45.6%	Utilzn	37.1%
4	4	30	VICTOZA	★	GLP-1 Receptor Agonists	2	12	42.5	\$17,876	\$1,489.68	\$3.43	\$3.60	\$0.39	-4.6%	Utilzn	-8.5%
5	59	5	MOUNJARO	★	GLP-1 Receptor Agonists	4	18	28.4	\$17,184	\$954.65	\$3.30	\$0.33	\$2.46	887.8%	Utilzn	884.3%
6	2	6	BIKTARVY		HIV-Multiclass Combo	1	4	30.0	\$13,077	\$3,269.17	\$2.51	\$4.11	\$2.11	-38.9%	Utilzn	-38.5%
7	27	7	FARXIGA	★	SGLT-2 Inhibitors & Combos	5	24	30.0	\$12,988	\$541.16	\$2.49	\$0.93	\$1.72	167.4%	Utilzn	158.4%
8	10	15	ENTRESTO		Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	12	50.0	\$12,417	\$1,034.78	\$2.38	\$1.88	\$0.91	26.5%	Utilzn	19.6%
9	9	22	JANUMET	★	DPP-4 Inhibitors & Combos	3	19	36.3	\$11,864	\$624.42	\$2.28	\$2.42	\$0.48	-6.0%	Utilzn	-11.6%
10	14	9	JANUVIA	★	DPP-4 Inhibitors & Combos	3	22	30.0	\$11,092	\$504.20	\$2.13	\$1.59	\$1.48	33.5%	Utilzn	31.6%
11	29	13	HUMALOG KWIKPEN	★	Insulin	6	21	26.5	\$9,444	\$449.72	\$1.81	\$0.85	\$0.95	114.4%	Utilzn	113.4%
12	11	10	LANTUS SOLOSTAR		Insulin ★	10	26	36.1	\$8,998	\$346.07	\$1.73	\$1.78	\$1.23	-3.1%	Cost	-19.8%
13	1	139	STRIBILD		HIV-Multiclass Combo	1	2	30.0	\$8,621	\$4,310.33	\$1.65	\$5.24	\$0.06	-68.4%	Utilzn	-73.1%
14	18	4	ELIQUIS		Oral Anticoagulants	3	15	30.0	\$7,844	\$522.97	\$1.51	\$1.31	\$2.53	15.4%	Utilzn	8.1%
15	-	8	WEGOVY		Anti-Obesity Agents	2	6	28.3	\$7,753	\$1,292.14	\$1.49	\$0.00	\$1.49	-	-	-
16	22	70	NOVOLOG FLEXPEN	★	Insulin	5	12	37.1	\$7,232	\$602.70	\$1.39	\$1.24	\$0.15	11.6%	Cost	14.9%
17	20	717	HUMALOG MIX 50/50 KWIKPEN		Insulin ★	1	3	90.0	\$7,223	\$2,407.72	\$1.39	\$1.28	\$0.01	8.6%	Utilzn	7.7%
18	17	109	BYDUREON BCISE		GLP-1 Receptor Agonists ★	1	9	28.7	\$6,973	\$774.75	\$1.34	\$1.34	\$0.08	0.2%	Cost	3.0%
19	43	11	XARELTO		Oral Anticoagulants	2	6	70.0	\$6,890	\$1,148.29	\$1.32	\$0.59	\$1.18	123.2%	Utilzn	115.3%
20	24	65	TRESIBA FLEXTOUCH	★	Insulin	2	13	19.2	\$6,307	\$485.19	\$1.21	\$1.03	\$0.18	17.0%	Cost	23.5%
Total						42	313	34.9	\$253,905	\$811.20	\$48.73	\$37.26	\$30.06	30.8%		39.8%
Plan Total						388	5,125	30.8	\$505,688	\$98.67	\$97.06	\$95.47	\$87.28	1.7%		2.1%

Top 20 specialty

All meds are Brands except indicated with a “G” for generic

Rank			Trend components												
Cu ↕	Pv ↕	Bench ↕	Drug name ↕	Therapy class ↕	Utilizr ↕	Rxs ↕	Avg days supply ↕	Total plan paid ↕	Plan paid per Rx ↕	Curr plan paid PMPM ↕	Prev plan paid PMPM ↕	Bench plan paid PMPM ↕	% Trend ↕	Top driver ↕	% Top driver ↕
1	1	3	DUPIXENT	Chronic Inflammatory Disease	4	31	27.5	\$106,016	\$3,419.86	\$20.35	\$11.35	\$3.11	79.2%	Utilzn	72.8%
2	-	4	SKYRIZI PEN	Chronic Inflammatory Disease	1	4	43.0	\$81,374	\$20,343.62	\$15.62	\$0.00	\$2.73	-	-	-
3	2	1	HUMIRA PEN	Chronic Inflammatory Disease	1	9	28.0	\$64,162	\$7,129.14	\$12.32	\$9.98	\$8.73	23.4%	Cost	9.6%
4	-	40	KISQALI	Oncology	1	4	28.0	\$60,778	\$15,194.42	\$11.67	\$0.00	\$0.26	-	-	-
5	-	14	IBRANCE	Oncology	1	2	28.0	\$31,090	\$15,545.22	\$5.97	\$0.00	\$0.74	-	-	-
6	-	228	TRIPTODUR	LHRH/GNRH Agonist/Antagonists	1	1	168.0	\$19,771	\$19,770.81	\$3.79	\$0.00	\$0.03	-	-	-
7	4	9	OTEZLA	Chronic Inflammatory Disease	1	2	30.0	\$9,465	\$4,732.70	\$1.82	\$0.70	\$1.25	158.6%	Cost	158.6%
8	-	5	TALTZ	Chronic Inflammatory Disease	1	1	28.0	\$6,940	\$6,940.24	\$1.33	\$0.00	\$2.00	-	-	-
9	3	193	MYCOPHENOLATE MOFETIL	Transplant G	1	3	90.0	\$4,415	\$1,471.57	\$0.85	\$0.79	\$0.04	7.7%	Utilzn	7.7%
10	5	192	TACROLIMUS	Transplant G	1	6	90.0	\$2,731	\$455.19	\$0.52	\$0.49	\$0.04	7.7%	Utilzn	7.7%
Total					10	63	39.9	\$386,743	\$6,138.77	\$74.23	\$23.31	\$19.71	218.5%		75.6%
Plan Total					10	63	39.9	\$386,743	\$6,138.77	\$74.23	\$23.31	\$59.98	218.5%		75.6%

5 out of the top 10 are for Chronic Inflammatory Disease

5 out of the top 10 have moved up in rank